What diseases is Everolimus suitable for treating?

Everolimus tablets are a selective immunosuppressive drug with broad anti-tumor activity.

Everolimus tablets are suitable for adult patients with advanced renal cell carcinoma who have failed previous treatment with sunitinib or sorafenib. Renal cell carcinoma is a malignant tumor originating from the renal tubular epithelium, accounting for 80% to 90% of renal malignant tumors. For such patients, everolimus tablets can be used as an effective second-line or third-line treatment option to help control the disease and prolong survival.

For adult patients with unresectable, locally advanced or metastatic, well-differentiated (moderately differentiated or highly differentiated) advanced pancreatic neuroendocrine tumors, everolimus tablets also show good therapeutic effects. Pancreatic neuroendocrine tumors are a type of tumor originating from pancreatic endocrine cells. Everolimus tablets can control the disease by inhibiting the growth and proliferation of tumor cells.

Everolimus tablets are also an effective treatment for adult patients with unresectable, locally advanced or metastatic, well-differentiated advanced non-functional gastrointestinal or pulmonary neuroendocrine tumors (NET). This type of tumor usually originates from neuroendocrine cells in the gastrointestinal tract or lungs. Everolimus tablets can inhibit the growth and spread of tumors through its unique mechanism of action.

Everolimus tablets are also indicated for the treatment of tuberous sclerosis complex (TSC)-related subependymal giant cell astrocytomas (SEGA) adult and pediatric patients, and adult patients with tuberous sclerosis-associated renal angiomyolipoma (TSC-AML) who do not require immediate surgical treatment. Tuberous sclerosis is a rare genetic disease that causes benign tumors in multiple organs. Everolimus tablets have shown significant efficacy in the treatment of such diseases, and can effectively control the growth of tumors and improve the quality of life of patients.